Patients with ≥1 completely or partially hypertrophic capillary malformation not exclusively located in the skin of the face, the skin overlying joints or in mucosal tissue Age ≥18 years Fitzpatrick skin type 1–3 without evident sun tan
| Patients with capillary malformations exclusively located in the face, in the skin overlying joints or in mucosa Pregnant or breastfeeding women Women with childbearing potential not using contraception Patients with chronic renal dysfunction with a glomerular filtration rate of <50 mL/min Patients with chronic pulmonary dysfunction, active pulmonary infections or previous bleomycin lung toxicity Patients with ataxia telangiectasia Patients with previous allergic reactions to bleomycin Patients who already received the maximum dose of bleomycin (400 units or 400 000 IU/m2) Patients with implanted electrical devices such as pacemakers or implantable cardioverter defibrillators Patients with clinically manifested arrhythmia Patients with epilepsy Patients who are not able to return to the hospital for follow-up visits Patients who are likely not able to understand the terms and risks of the study (eg, cognitive impairment) Legally incompetent adults Patients of which informed consent was not obtained
|